State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, Jiangsu 215123, China.
State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, Jiangsu 215123, China.
J Control Release. 2022 Jun;346:240-249. doi: 10.1016/j.jconrel.2022.04.029. Epub 2022 Apr 26.
Radioisotope therapy (RIT) of cancer is restrained by the nonspecific distribution of radioisotope and ineptitude for metastatic tumors. Meanwhile, the clinical application of immune checkpoint blockade (ICB) confronts problems such as low responsive rate, multiple administration requirements and immune-related adverse events (irAE). To address these challenges, we prepared an injectable suspension by immobilizing I-labeled anti-programmed cell death-ligand 1 antibody (αPD-L1) in bacterial cellulose for precise and durable radio-immunotherapy of cancer. The crisscross network structure of bacterial cellulose nanofibers would contribute to the long-term retention of I-labeled αPD-L1 within tumors, which could reduce the side effect stemmed from the nonspecific I distribution in normal tissues. The potent long-term RIT of I, combined with ICB by αPD-L1, could effectively restrain the growth of primary tumor in mice. In addition to the direct killing effect, I-αPD-L1 immobilized by bacterial cellulose could enhance the immunogenic cell death (ICD) of cancer cells, activating the maturation of multiple immune cells to induce a systemic anti-tumor immune effect. Our therapeutic strategy could suppress spontaneous cancer metastasis and prolong the survival time of tumor-bearing mice. This study proposed a new approach for combined radio-immunotherapy and a novel solution for tumor metastasis in advanced-stage cancers.
癌症的放射性同位素治疗(RIT)受到放射性同位素的非特异性分布和转移性肿瘤治疗能力的限制。同时,免疫检查点阻断(ICB)的临床应用面临着响应率低、多次给药要求和免疫相关不良事件(irAE)等问题。为了解决这些挑战,我们通过将放射性碘标记的抗程序性细胞死亡配体 1 抗体(αPD-L1)固定在细菌纤维素中来制备可注射悬浮液,以实现癌症的精确和持久的放射性免疫治疗。细菌纤维素纳米纤维的交错网络结构有助于放射性碘标记的 αPD-L1 在肿瘤内的长期保留,从而减少由于正常组织中放射性碘的非特异性分布而引起的副作用。强大的长期放射性碘治疗,结合αPD-L1 的 ICB,可有效抑制小鼠原发性肿瘤的生长。除了直接杀伤作用外,细菌纤维素固定的 I-αPD-L1 还可以增强癌细胞的免疫原性细胞死亡(ICD),激活多种免疫细胞的成熟,诱导全身性抗肿瘤免疫效应。我们的治疗策略可以抑制自发性癌症转移并延长荷瘤小鼠的生存时间。本研究提出了一种联合放射性免疫治疗的新方法,并为晚期癌症的肿瘤转移提供了一种新的解决方案。